Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • GEN-004: Phase IIa started

    Genocea Biosciences Inc. (NASDAQ:GNCA), Cambridge, Mass. Product: GEN-004 Business: Infectious Molecular target: NA Description: T cell vaccine against Streptococcus pneumoniae containing SP0148, SP1912 and SP2108 …

    Published on 9/22/2014
  • Hydroxychloroquine: Completed Phase I enrollment

    VG Life Sciences Inc. (Pink:VGLS), San Marino, Calif. Product: Hydroxychloroquine (HCQ) Business: Cancer Molecular target: NA Description: Hydroxychloroquine developed using Metabolic Disruption Technology (MDT) …

    Published on 9/22/2014
  • IV G1T28-1: Phase I started

    G1 Therapeutics Inc., Chapel Hill, N.C. Product: IV G1T28-1 Business: Cancer Molecular target: Cyclin dependent kinase 4 (CDK4); Cyclin dependent kinase 6 (CDK6) Description: Selective inhibitor of cyclin dependent …

    Published on 9/22/2014
  • Japanese cedar tree pollen allergy immunotherapy tablet: Phase II/III started

    ALK-Abello A/S (CSE:ALK-B), Horsholm, Denmark Torii Pharmaceutical Co. Ltd. (Tokyo:4551), Tokyo, Japan Product: Japanese cedar tree pollen allergy immunotherapy tablet (AIT) (TO-206) Business: Inflammation Molecular …

    Published on 9/22/2014
  • Lampalizumab: Phase III started

    Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Lampalizumab (FCFD4514S, RG7417) Business: Ophthalmic Molecular target: Complement factor D (CFD) (Adipsin) …

    Published on 9/22/2014
  • LPCN 1107: Phase I started

    Lipocine Inc. (NASDAQ:LPCN), Salt Lake City, Utah Product: LPCN 1107 Business: Genitourinary Molecular target: NA Description: Oral hydroxyprogesterone caproate (HPC) Indication: Prevent preterm birth Endpoint: Safety …

    Published on 9/22/2014
  • Novocart 3D: Phase III started

    Aesculap Inc., Center Valley, Pa. Product: Novocart 3D Business: Musculoskeletal Molecular target: NA Description: Scaffold assisted autologous chondrocyte implant Indication: Treat articular cartilage lesions of the …

    Published on 9/22/2014
  • NVR-1221: Phase Ib started

    Novira Therapeutics Inc., Radnor, Pa. Product: NVR-1221 Business: Infectious Molecular target: NA Description: Oral small molecule inhibitor of the HBV core or capsid protein Indication: Treat chronic HBV infection …

    Published on 9/22/2014
  • ODM-201: Phase III started

    Orion Corp. (HSE:ORNAV; HSE:ORNBV), Espoo, Finland Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: ODM-201 Business: Cancer Molecular target: Androgen receptor Description: Oral androgen receptor inhibitor …

    Published on 9/22/2014
  • Ondansetron: Phase III started

    RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL), Ramat-Gan, Israel Product: Ondansetron (RHB-102) Business: Gastrointestinal Molecular target: Serotonin (5-HT3) receptor Description: Once-daily controlled release …

    Published on 9/22/2014
  • Plazomicin: Phase III started

    Achaogen Inc. (NASDAQ:AKAO), South San Francisco, Calif. Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Product: Plazomicin (ACHN-490) Business: Infectious Molecular target: NA Description: Next-generation …

    Published on 9/22/2014
  • Pneumostem: Phase I/II start

    Medipost (KOSDAQ:078160), Seoul, South Korea Product: Pneumostem Business: Pulmonary Molecular target: NA Description: Allogeneic mesenchymal stem cells from umbilical cord blood Indication: Treat bronchopulmonary …

    Published on 9/22/2014
  • RHB-105: Phase III amended

    RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL), Ramat-Gan, Israel Product: RHB-105 (formerly Heliconda) Business: Infectious Molecular target: NA Description: Fixed-dose combination of the antibiotics rifabutin and…

    Published on 9/22/2014
  • Ruconest conestat alfa: Phase II started

    Pharming Group N.V. (Euronext:PHARM), Leiden, the Netherlands Product: Ruconest conestat alfa (rhC1INH, Rhucin) Business: Inflammation Molecular target: Complement 1 (C1) esterase Description: Recombinant human …

    Published on 9/22/2014
  • Twirla: Phase III started

    Agile Therapeutics Inc. (NASDAQ:AGRX), Princeton, N.J. Product: Twirla, Seven-day contraceptive patch (AG200-15) (formerly AG-200-15) Business: Endocrine/Metabolic Molecular target: Estrogen receptor; Progesterone …

    Published on 9/22/2014
  • Ublituximab: SPA received

    LFB S.A., Les Ulis, France TG Therapeutics Inc. (NASDAQ:TGTX), New York, N.Y. Ildong Pharmaceutical Co. Ltd. (KSE:000230), Seoul, South Korea Product: Ublituximab (TGTX-1101, TG-1101, LFB-R603) Business: Cancer …

    Published on 9/22/2014
  • XEN-D0103: Phase II started

    Xention Ltd., Cambridge, U.K. Product: XEN-D0103 Business: Cardiovascular Molecular target: Potassium channel Kv1.5 (KCNA5) Description: Selective potassium channel Kv1.5 (KCNA5) antagonist Indication: Treat paroxysmal …

    Published on 9/22/2014
  • Aldoxorubicin: Phase Ib started

    CytRx Corp. (NASDAQ:CYTR), Los Angeles, Calif. Product: Aldoxorubicin (formerly DOXO-EMCH, INNO-206) Business: Cancer Molecular target: DNA Description: 6-maleimidocaproyl hydrazone prodrug of doxorubicin Indication: …

    Published on 9/15/2014
  • ALKS 7106: Phase I started

    Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Product: ALKS 7106 Business: Neurology Molecular target: NA Description: Oral small molecule opioid analgesic Indication: Treat pain Endpoint: Safety and pharmacokinetics …

    Published on 9/15/2014
  • AVP-786: Phase II started

    Avanir Pharmaceuticals Inc. (NASDAQ:AVNR), Aliso Viejo, Calif. Concert Pharmaceuticals Inc. (NASDAQ:CNCE), Lexington, Mass. Product: AVP-786, CTP-786 (formerly deuterated dextromethorphan) Business: Neurology Molecular …

    Published on 9/15/2014
  • BL-8040: Phase I started

    Biokine Therapeutics Ltd., Tel Aviv, Israel BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Jerusalem, Israel Product: BL-8040 (formerly BKT-140) Business: Hematology Molecular target: CXC chemokine receptor 4 (CXCR4) (…

    Published on 9/15/2014
  • CB-5083: Phase I started

    Cleave Biosciences Inc., Burlingame, Calif. Product: CB-5083 Business: Cancer Molecular target: Valosin containing protein (VCP) (p97) Description: A highly selective valosin containing protein (VCP; p97) inhibitor …

    Published on 9/15/2014
  • CureXcell: Completed Phase III enrollment

    Macrocure Ltd. (NASDAQ:MCUR), Petah Tikva, Israel Product: CureXcell Business: Dermatology Molecular target: NA Description: Suspension containing activated allogeneic white blood cells isolated from the peripheral …

    Published on 9/15/2014
  • DiaPep277: Development discontinued

    Evotec AG (Xetra:EVT), Hamburg, Germany Hyperion Therapeutics Inc. (NASDAQ:HPTX), South San Francisco, Calif. Product: DiaPep277 Business: Endocrine/Metabolic Molecular target: NA Description: Peptide composed of 24 …

    Published on 9/15/2014
  • Emricasan: Phase II started

    Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), San Diego, Calif. Product: Emricasan (PF-3491390, IDN-6556, PF-03491390) Business: Hepatic Molecular target: Caspases Description: Pan-caspase inhibitor Indication: Treat …

    Published on 9/15/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993